These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 10955074)

  • 1. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
    Leibovici D; Zisman A; Lindner A
    Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074
    [No Abstract]   [Full Text] [Related]  

  • 2. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
    Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL
    J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

  • 4. BCG in carcinoma in situ and superficial bladder tumors.
    Lamm DL
    Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069
    [No Abstract]   [Full Text] [Related]  

  • 5. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
    McHugh LA; Griffiths TR
    BJU Int; 2004 Jul; 94(1):193. PubMed ID: 15217467
    [No Abstract]   [Full Text] [Related]  

  • 6. BCG vaccine in urinary bladder cancer.
    Brosman SA
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
    [No Abstract]   [Full Text] [Related]  

  • 7. Follow-up of the effect of BCG vaccine treatment in bladder tumour patients.
    Kulcsár G; Nász I; Tenke P; Csata S
    Acta Microbiol Hung; 1993; 40(2):151-7. PubMed ID: 8184669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer in 2014: From the genomic frontier to immunotherapeutics.
    Lenis AT; Chamie K
    Nat Rev Urol; 2015 Feb; 12(2):74-6. PubMed ID: 25558841
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment modalities in superficial bladder cancer.
    Irwin R; Zincke H; Droller MJ; Prout GR; Soloway MS
    Semin Urol; 1989 Feb; 7(1 Suppl 1):1-12. PubMed ID: 2499916
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of superficial carcinoma of the bladder.
    Paulson DF
    Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy for the treatment of superficial and infiltrative bladder carcinoma.
    Cockett AT; Merguerian PA; di Sant'Agnese PA; Wheeless LL
    Prog Clin Biol Res; 1989; 303():455-62. PubMed ID: 2675003
    [No Abstract]   [Full Text] [Related]  

  • 12. [Review of the value of BCG maintenance therapy in superficial bladder tumours].
    Peyromaure M; Zerbib M
    Prog Urol; 2004 Feb; 14(1):105-8. PubMed ID: 15098767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [International Consensus Panel--treatment strategies for superficial bladder cancer].
    Adler S; St Niclas M
    Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
    [No Abstract]   [Full Text] [Related]  

  • 14. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours.
    Lebret T; Watson RW; Molinié V; Poulain JE; O'Neill A; Fitzpatrick JM; Botto H
    Eur Urol; 2007 Jan; 51(1):161-6; discussion 166-7. PubMed ID: 16828965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
    Bochner BH
    Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
    [No Abstract]   [Full Text] [Related]  

  • 18. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract]   [Full Text] [Related]  

  • 19. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
    Yates J; Stein B
    Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
    Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.